Brief: Hansa Biopharma Announces Temporary Marketing Authorization In Switzerland
13/05/2022 07:10
May 13 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA ANNOUNCES TEMPORARY MARKETING
AUTHORIZATION IN
SWITZERLAND FOR IDEFIRIX ® (IMLIFIDASE) IN KIDNEY
TRANSPLANTATION
* USE OF IDEFIRIX® IN SWITZERLAND IS RESERVED FOR PATIENTS
WITH A
LOW PROBABILITY OF BEING TRANSPLANTED
Source text for Eikon: ID:nWkr38TDk7
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS